STAR0502 / Marengo, Ipsen - LARVOL DELTA

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen (PRNewswire) - "Marengo Therapeutics, Inc...announced that Ipsen...has nominated the first clinical drug candidate (DC) of two from its multi-year strategic partnership in oncology....This nomination represents the first of two selective T cell activation repertoire (STAR) T cell bi-functional activator programs that Marengo and Ipsen will advance as part of the collaboration."

New molecule • Oncology • Solid Tumor